Terms: = Liver cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Staging
17 results:
1. Effects of MFG-E8 expression on the biological characteristics of ovarian cancer cells via the AKT/mtor/S6K signalling pathway.
Li N; Wang Y; Liu L; Wang P; Wu X
J Obstet Gynaecol; 2023 Dec; 43(1):2151354. PubMed ID: 36484512
[TBL] [Abstract] [Full Text] [Related]
2. Midkine Promotes Metastasis and Therapeutic Resistance via mtor/RPS6 in Uveal Melanoma.
Karg MM; John L; Refaian N; Buettner C; Rottmar T; Sommer J; Bock B; Resheq YJ; Ksander BR; Heindl LM; Mackensen A; Bosch JJ
Mol Cancer Res; 2022 Aug; 20(8):1320-1336. PubMed ID: 35503453
[TBL] [Abstract] [Full Text] [Related]
3. circNFATC3 sponges miR-548I acts as a ceRNA to protect NFATC3 itself and suppressed hepatocellular carcinoma progression.
Jia C; Yao Z; Lin Z; Zhao L; Cai X; Chen S; Deng M; Zhang Q
J Cell Physiol; 2021 Feb; 236(2):1252-1269. PubMed ID: 32667692
[TBL] [Abstract] [Full Text] [Related]
4. Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma.
Yu XN; Zhang GC; Sun JL; Zhu HR; Shi X; Song GQ; Weng SQ; Dong L; Liu TT; Shen XZ; Guo HY; Zhu JM
Ann Surg Oncol; 2020 May; 27(5):1546-1557. PubMed ID: 32157528
[TBL] [Abstract] [Full Text] [Related]
5. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract] [Full Text] [Related]
6. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mtor Signaling Pathway.
Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
[No Abstract] [Full Text] [Related]
7. MicroRNA‑601 serves as a potential tumor suppressor in hepatocellular carcinoma by directly targeting PIK3R3.
Song Y; He S; Zhuang J; Wang G; Ni J; Zhang S; Ye Y; Xia W
Mol Med Rep; 2019 Mar; 19(3):2431-2439. PubMed ID: 30664174
[TBL] [Abstract] [Full Text] [Related]
8. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract] [Full Text] [Related]
9. [Insight and judgment on recurrence of hepatocellular carcinoma after liver transplantation].
Zheng H; Zhang HM; Zheng WP
Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):88-92. PubMed ID: 29804372
[TBL] [Abstract] [Full Text] [Related]
10. Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection.
Kirste S; Kayser G; Zipfel A; Grosu AL; Brunner T
Radiat Oncol; 2018 Feb; 13(1):28. PubMed ID: 29463266
[TBL] [Abstract] [Full Text] [Related]
11. MAF1 suppresses AKT-mtor signaling and liver cancer through activation of PTEN transcription.
Li Y; Tsang CK; Wang S; Li XX; Yang Y; Fu L; Huang W; Li M; Wang HY; Zheng XF
Hepatology; 2016 Jun; 63(6):1928-42. PubMed ID: 26910647
[TBL] [Abstract] [Full Text] [Related]
12. Examinations of Factors Influencing Survival of liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract] [Full Text] [Related]
13. Integration of genomic information in the clinical management of HCC.
Quetglas IM; Moeini A; Pinyol R; Llovet JM
Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):831-42. PubMed ID: 25260311
[TBL] [Abstract] [Full Text] [Related]
14. Neuroendocrine tumours of the small intestine.
Strosberg J
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):755-73. PubMed ID: 23582917
[TBL] [Abstract] [Full Text] [Related]
15. Strategies of immunosuppression for liver transplant recipients with hepatocellular carcinoma.
Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Varo-Pérez E
Transplant Proc; 2011 Apr; 43(3):711-3. PubMed ID: 21486580
[TBL] [Abstract] [Full Text] [Related]
16. Pilot study: rapamycin in advanced hepatocellular carcinoma.
Schöniger-Hekele M; Müller C
Aliment Pharmacol Ther; 2010 Sep; 32(6):763-8. PubMed ID: 20629977
[TBL] [Abstract] [Full Text] [Related]
17. The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake.
Jiang X; Kenerson H; Aicher L; Miyaoka R; Eary J; Bissler J; Yeung RS
Am J Pathol; 2008 Jun; 172(6):1748-56. PubMed ID: 18511518
[TBL] [Abstract] [Full Text] [Related]
